Gerhard Koenig

This inventor holds 6 USPTO granted patents and 12 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Envivo Pharmaceuticals, Inc., Forum Pharmaceuticals, Inc., Axovant Sciences Gmbh. Active years: 2013-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gerhard Koenig. Retrieved from https://idiyas.com/inventor/gerhard-koenig

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 12)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 6(Granted Patents)

Company Filing History:

2 out of 13

Envivo Pharmaceuticals, Inc.

patents

2 out of 9

Forum Pharmaceuticals, Inc.

patents

1 out of 8

Axovant Sciences Gmbh

patents

4. 1 out of 44

Ironwood Pharmaceuticals, Inc.

patents

Years Active: 2013-2019

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10183938 - Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors (2019-01-22),

2. 9585877 - Methods of maintaining, treating or improving cognitive function (2017-03-07),

3. 9540380 - Imidazotriazinone compounds (2017-01-10),

4. 8815933 - Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (2014-08-26),

5. 8642638 - Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (2014-02-04),

6. 8569354 - Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (2013-10-29),

Title: The Innovative Contributions of Gerhard Koenig

Introduction

Gerhard Koenig is a notable inventor based in Newton, MA, who has made significant contributions to the field of pharmaceuticals. With a total of six patents to his name, he has focused on developing compounds that enhance cognitive function.

Latest Patents

One of his latest patents is titled "Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotinic acetylcholine receptors." This invention relates to novel geminal substituted quinuclidine amide compounds and their pharmaceutical compositions, which are suitable as agonists or partial agonists of α7-nAChR. The patent outlines methods for preparing these compounds and compositions, as well as their use in maintaining, treating, and improving cognitive function. Specifically, it describes methods for administering the compound or composition to patients with cognitive deficiencies or those seeking to enhance cognitive function.

Career Highlights

Throughout his career, Gerhard Koenig has worked with various companies, including Forum Pharmaceuticals, Inc. and Envivo Pharmaceuticals, Inc. His work has been instrumental in advancing pharmaceutical research and development.

Collaborations

Gerhard has collaborated with notable individuals in the field, including Richard Chesworth and Gideon Shapiro. These collaborations have contributed to the success of his innovative projects.

Conclusion

Gerhard Koenig's work exemplifies the impact of innovation in the pharmaceutical industry, particularly in the realm of cognitive enhancement. His patents and collaborations highlight his commitment to improving cognitive function through scientific advancements.

Profile summary based on public USPTO records.